- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The global HIV epidemic claimed fewer lives in 2015 than at any point in almost two decades, and fewer people became newly infected with HIV than in any year since 1991. The list of countries on the brink of eliminating new HIV infections among children keeps growing. A massive expansion of antiretroviral therapy (ART) has reduced the global number of people dying from HIV-related causes to about 1.1 million in 2015 – 45% fewer than in 2005. UNAIDS/WHO estimates show that more than 18 million people were receiving ART in mid-2016.
The Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive (Global Plan) was launched in June 2011. It prioritizes the 22 countries1 that, in 2009, accounted for 90% of the global number of pregnant women living with HIV who were in need of services to prevent mother-to-child transmission of HIV. This report summarizes the history and development of the Global Plan, its achievements in reaching ambitious goals, lessons learned and directions for future progress to end new HIV infections among children.
Keywords: HIV, infections, children, prevention, antiretroviral medicines, pregnant women, breastfeeding
See Regional Progress Hepatitis B Vaccination Coverage, 1990—2015, Regional Progress: Status of the 2017 Hepatitis B Control Milestone of <1% HBsAg Prevalence among 5 year old children
This year World Antibiotic Awareness Week will be held from 14 to 20 November 2016. The campaign aims to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers, policy-makers and the agriculture sector to avoid the further emergence and spread of antibiotic resistance.
The 10th Asia-Pacific United Nations Prevention of Parent-To-Child Transmission (PPTCT) of HIV and Syphilis Task Force meeting was held from 15 to 17 September 2015 in Beijing, China. More than 230 participants from 19 Asia-Pacific countries, including 90 participants from provinces in China, as well as civil society and United Nations partners attended the meeting. The meeting focused on steps towards achieving and validating the elimination of parent-to-child transmission (EPTCT) of infectious diseases, and the integration of services to contribute to improving maternal and child health (MCH) outcomes.
Communicable diseases such as HIV, TB and malaria remain among the leading causes of illness, death and impoverishment in our region, and infection levels continue to rise in many settings and populations. Unless focused efforts are undertaken to build on the gains to date, communities that remain vulnerable to neglected tropical diseases such as leprosy, kala-azar and filariasis will continue to be left behind. This report focuses on the historic opportunity for the WHO South-East Asia Region to end the scourge of communicable diseases for good.
Keywords: HIV, TB, malaria, neglected tropical diseases, public health
This infographic details the process for developing long-acting injectables for PrEP and treatment.
Keywords: HIV, ARV, PrEP, treatment, prevention, testing
Syphilis, a sexually transmitted bacterial infection, affects almost 40 million people worldwide. Like HIV, it can be passed from a pregnant woman to her unborn child. In pregnancy, if untreated, syphilis can result in severe outcomes for mother and infant. Yet, transmission can be effectively prevented with inexpensive and easily available penicillin treatment for pregnant women.6 Recognizing the opportunity to test and treat mothers and babies during antenatal or perinatal care, in 2007, the WHO and its partners published the Global elimination of congenital syphilis: rationale and strategy for action. The goal was to increase the number of pregnant women tested for syphilis to 90 per cent and to provide adequate treatment to at least 90 per cent of seropositive pregnant women by 2015.
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome. It also provides information on the production of new hepatitis C drugs and generic versions worldwide, including where the drugs are registered, where the drugs are patented and where not, and what opportunities countries have under the license agreements that were signed by some companies as well as current pricing of all recommended DAAs, including by generic companies all over the world.
Keywords: HIV, hepatitis C, HCV, treatment, diagnosis, testing
The World Health Organization (WHO) is committed to ensuring that the great success of HIV treatment scale-up is not threatened by HIV drug resistance (HIVDR). Preventing HIVDR is an important part of meeting the 90-90-90 targets by the year 2020.
The development of a five-year plan reflects a global consensus that HIVDR in lower and middle-income countries requires a coordinated and resourced response. The Global Action Plan is an agreement by key partners about their respective roles in preventing, monitoring, and responding to HIVDR.